Hematologic Protection
Cross-source consensus on Hematologic Protection from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Highlighted claims
- The intended mechanism is that GO depletes residual CD33-positive cells while sparing CD33-deleted donor hematopoiesis. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- Sustained neutrophil and platelet counts suggest trem-cel reduces the prolonged cytopenias historically associated with GO after standard alloHCT. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- At 2 mg/m2, GO produced measurable concentrations through the dosing interval without materially increasing peak concentration. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- Lower CD33 target density after CD33-deleted transplantation likely slowed GO clearance. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- The pharmacokinetic pattern after trem-cel suggests a potentially broader therapeutic index for GO. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial